Progression of renal failure and hypertensive nephrosclerosis  by Zucchelli, Pietro & Zuccalá, Alessandro
Progression of renal failure and hypertensive nephrosclerosis
PIETRO ZUCCHELLI and ALESSANDRO ZUCCALA´
Malpighi Department of Nephrology, Policlinico S. Orsola-Malpighi, Bologna, Italy
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Data provided by end-stage renal disease (ESRD) registries
document a progressive and striking increase in the incidence of
hypertension-related ESRD over the years, and its prevalence
supports the classic statement that the kidney may be a victim of
hypertension. Two clinical conditions should be considered sepa-
rately when the role of hypertension in progressive renal disease
is discussed: (a) hypertension and primary renal disease and (b)
progressive renal disease in essential hypertension. The appear-
ance of systemic hypertension is one of the major risk factors for
the progressive deterioration of primary renal disease both in
experimental models and in humans. Strict blood pressure control
is able to significantly reduce the disease progression to renal
failure. Angiotensin-converting enzyme inhibitors probably show
a better nephroprotective action than other antihypertensive
agents. Long-lasting hypertension may induce ESRD in some
patients through hypertensive nephrosclerosis. In many cases of
progressive renal disease associated with essential hypertension,
particularly in elderly Caucasians, atheromatous renovascular
disease via renal artery stenosis and/or cholesterol microemboli-
zation represent the main cause of ESRD.
Ever since Volhard and Fahr published their observa-
tions in 1914, arterial hypertension has been considered an
important cause of progressive renal disease [1]. The role
of hypertension in chronic renal failure has received grow-
ing interest recently as a result of the data provided by
end-stage renal disease (ESRD) registries in several coun-
tries. Many of these registries have observed a progressive
and striking increase in cases of hypertension-related
ESRD [2, 3].
To analyze the relationship between hypertension and
progressive renal disease, two different clinical conditions
should be separately considered: (a) the role of hyperten-
sion in the progression of primary renal diseases; (b) the
appearance of chronic renal failure in essential hyperten-
sion. We attempt to discuss these two aspects in this article.
PROGRESSION OF PRIMARY RENAL DISEASES
A progressive deterioration in renal function inexorably
occurs in most forms of chronic renal disease following a
critical reduction in functioning renal mass [4]. Several risk
factors have been reported to be critical for this relentless
progression, among which are maladaptive glomerular hy-
perfiltration and hypertension [5], as well as the appearance
of systemic hypertension. Many models of experimental
renal disease as well as the remnant kidney models (sum-
marized in Table 1) have clearly documented that the
superimposition of systemic hypertension induces or accel-
erates the progression of renal disease, whereas the same
disease without hypertension either has no or a very slow
progression [6–10]. In addition, the control of systemic
hypertension reduces proteinuria and prevents renal func-
tion deterioration [7, 11]. Systemic hypertension probably
acts through the elevation in filtration pressure as a conse-
quence of the loss of glomerular autoregulation [10]. A
unifying hypothesis suggests that intraglomerular hemody-
namic alteration is responsible for an elevated fluid shear
stress [12]. This phenomenon may induce two types of
events: (a) an enhanced production of proinflammatory
cytokines and fibrogenic growth factors leading to the
production and accumulation of mesangial extracellular
matrix; (b) an increased transcapillary protein traffic and
proteinuria that may induce a cascade of events leading to
tubulointerstitial scarring [13]. Glomerulosclerosis and tu-
bulointerstitial scarring represent the main mechanisms for
the vicious cycle leading to ESRD.
Angiotensin II seems to play a central role in those
mechanisms. In fact, elevation of systemic and intraglo-
merular pressures, mesangial macromolecules trapping,
selective defect in the glomerular barrier, glomerular hy-
pertrophy as well as profibrotic action particularly through
tranforming growth factor-B (TGF-b) overexpression, en-
dothelin 1 expression and secretion, and tubulointerstitial
fibrogenic effect are all actions produced by angiotensin II
receptor type-1 (AT1) stimulation [13–15]. A strong point
in favor of the above reported hypothesis is the finding that
the administration of angiotensin converting enzyme inhib-
itors (ACEi) is associated with the slowing down of renal
damage. After the work by Anderson, Rennke and Brenner
more than 10 years ago [16], an impressive number of
further experiments have clearly documented that by using
ACEi, and possibly angiotensin II-receptor antagonists as
well, an important slowing in renal disease progression
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takes place, together with an important reduction in pro-
teinuria and in the severity of glomerulosclerosis and
tubulointerstitial scarring and fibrosis [17].
Arterial hypertension is a common sign in human renal
disease not only in the presence of renal insufficiency but
even when renal function is quite normal [18]. In addition,
in patients with IgA nephropathy considered normotensive
because the casual blood pressure was less than 140/90
without medication, a slight but significant elevation of
ambulatory blood pressure was documented that was asso-
ciated with an increased left ventricular mass index [19].
Notwithstanding the frequency of hypertension in the renal
disease, its potential role in the progression of renal failure,
which has been postulated for decades, has only recently
received direct evidence in several retrospective studies [20,
21] and particularly in some prospective trials. In fact, in a
few formal prospective, randomized trials aimed at verify-
ing the role of protein restriction in slowing down or halting
the progression of renal failure, blood pressure strongly
predicted the faster decline in GFR (associated to other
independent risks) [22–24]. Indeed, in theModification of
Diet in Renal Disease (MDRD) Study, the difference in
mean arterial pressure between the usual and low blood
pressure groups during the follow-up, which was equal to
4.7 mm Hg, had a significant and important effect in
reducing the progression of renal disease in patients with
proteinuria greater than 1 g/24 hr [24]. Therefore, arterial
hypertension is an important risk factor for renal disease
progression and its normalization is able to significantly
reduce the rate of progression.
The experimental data of the 1980s offered evidence
regarding the superiority of ACEi over other antihyperten-
sive agents in mitigating the progression. These data pro-
vided the rationale for clinical studies with the use of ACEi
both in diabetic and non-diabetic nephropathies.
In diabetic nephropathy, many trials have documented
that antihypertensive therapy, and particularly the use of
ACEi, is able to reduce microalbuminuria and to prevent
the fall in GFR [25]. Two trials in particular have carefully
analyzed the progression of diabetic nephropathy: Ravid et
al have followed 94 patients with non-insulin diabetic
mellitus at the early phase of nephropathy [26]. ACEi
resulted in long-term (5 year) stabilization of albuminuria
and the preservation of the serum creatinine level. Lewis et
al have published the results of a collaborative study in
insulin-dependent diabetes mellitus with overt nephropathy
[27]. After a three year follow-up the risk of doubling of
serum creatinine concentration was reduced by 50% in the
ACEi group compared to placebo. These and other data
offered Parving et al the chance to calculate the cumulative
death rate of overt diabetic nephropathy. These authors
found that from the 94% value at 15 years, the death rate
can be reduced to 45% with standard antihypertensive
treatment and to 10 to 15% with ACEi [28].
Regarding non-diabetic nephropathies, we published the
results of a prospective randomized multicenter trial in
1992 [29]. Since then, many reports based on prospective
trials have reported the beneficial effects of ACEi on renal
disease that seem to be greater than the effects on blood
pressure [30–32]. The very large double-blind AIPRI trial
[33] on 583 patients with renal insufficiency recruited from
49 European hospitals (in France, Germany and Italy)
documented a 53% overall reduction in the risk of doubling
serum creatinine with benazepril than other antihyperten-
sive therapy. The reduction in the risk was greater in
patients with mild renal insufficiency and in those with
proteinuria greater than 1 g/24 hr. A very recent meta-
analysis has combined information from all the randomized
ACEi trials in patients with non-diabetic renal disease [34].
Among 806 patients receiving ACEi, 6.4% developed
ESRD in comparison to 9.1% of the 788 controls. The
conclusion of this analysis is that ACEi are more effective
than other antihypertensive agents in reducing the devel-
opment of ESRD without increasing mortality. Table 2
summarizes some of the published trials.
It has been suggested that these ACEi protective effects
were related to the better control of systemic and intrarenal
pressure, as experimentally put forward by the work of
Griffin et al [35], or to the non-hemodynamic factors cited
before. In the AIPRI study, as in many other trials, mean
blood pressure values during the study period were con-
stantly and significantly lower (by around 5 mm Hg) in the
ACEi group compared to the “placebo” one. The question
of whether the renal protection of ACEi is related to
hemodynamic or non-hemodynamic factors therefore re-
main unsolved. Notwithstanding these doubts, the level of
blood pressure control, obtained particularly with ACEi, is
an important variable in preserving renal function. A
post-hoc analysis of the MDRD study suggests that in
patients with proteinuria greater than 1 g/24 hours, a
reduction in the mean blood pressure to around 92 mm Hg
is required in order to achieve an important slowing in the
progression of renal insufficiency [36]. Can we conclude
Table 1. Role of systemic hypertension in experimental renal disease
Model Study Reference
Mesangial ferritin-antiferritin IC
nephritis
Raij, et al, 1984 [6]
Autologous immune complex
nephritis
Okuda et al, 1986 [7]
Adriamicin-induced focal glomerular
sclerosis
Okuda et al, 1986 [7]
AntiGBM nephritis and 2K1C
hypertension
Blantz et al, 1987 [8]
Nephrotoxic serum nephritis Neugarten et al, 1988 [9]
The presence of systemic hypertension may cause or worsen progressive
renal injury.
Remnant kidney model Bidani et al, 1987 [10]
The absence of progressive nephron loss when normal blood pressure is
present.
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that we have completely understood the mechanism of
renal disease progression? In other words, is systemic and
glomerular hypertension/hypertrophy directly or through
proteinuria the sole culprit of progressive renal damage?
We do not believe this is so. In fact, some renal diseases,
such as polycystic kidney disease, do progress to ESRD
with a trivial proteinuria and in these diseases ACEi and/or
a perfect blood pressure control do not exert protection, as
documented both in the AIPRI [33] and MDRD [23]
studies. In addition, calcium antagonists seem to influence
progression differently in different renal diseases [39].
Therefore, at least two different progression pathways may
exist: one in which progression is strongly associated with
systemic and intraglomerular hypertension and with pro-
teinuria and in which ACEi are likely to be the first-choice
drug [37]; and the second in which proteinuria is mild or
absent, probably without an important role of systemic and
intraglomerular pressure, which might respond better to
calcium antagonists. This aspect requires much further
research.
APPEARANCE OF RENAL FAILURE IN ESSENTIAL
HYPERTENSION
There has been growing interest in the topic of hyper-
tension-induced ESRD, mostly due to the data produced by
the ESRD registries [1, 2]. In fact, an increasing prevalence
and incidence of hypertensive nephropathy as the cause of
ESRD is now the most regular finding both in the USA and
in Europe, accounting for 26 to 29% of all ESRD patients
[38]. Nevertheless, the causative role of non-malignant
essential hypertension for ESRD has been questioned, if
not refuted by many researchers, given the contrasting
experimental, morphological, and particularly the epidemi-
ological and clinical observations [39, 40]. The explanation
for the discrepances between the high prevalence of ESRD
classified as being due to hypertension and these contrast-
ing data may lie in the widespread use of the same code
utilized by the ESRD Registries for different diseases (as
shown in Table 3), no doubt causing much confusion [41].
In a retrospective study of ours that was performed on
136 patients diagnosed as having benign nephrosclerosis on
clinical grounds, a thorough diagnostic workup, including
renal biopsy, disclosed true nephrosclerosis in 44.1% of the
patients, whereas renovascular hypertension and/or choles-
terol emboli accounted for 30 to 40% of the cases [41, 42].
In addition, a prospective study on 58 conservative patients
who satisfied the selection criteria for clinical hypertensive
nephrosclerosis (Table 4), atheromatous renovascular dis-
ease was found in 32% of the patients, while true hyper-
tensive nephrosclerosis was confirmed in the 46%.
Therefore, at least two important variants comprise
ESRD related to hypertension: hypertensive nephrosclero-
sis and atheromatous renal disease [43, 44].
HYPERTENSIVE NEPHROSCLEROSIS
From our data we can calculate that in the Caucasian
population the risk of developing renal failure corresponds
to 10 to 15% of the annual ESRD incidence due to
hypertension, that is, 10 to 20 new cases every year. This
estimate in Caucasians is similar to the number of cases per
every 6000 essential hypertensives, as suggested by Raine
[45].
The risk of kidney damage in hypertension is quite
different for African Americans. In the black population
the risk of ESRD is significantly greater [40]. The kidneys
of black and white hypertensives have many important
physiological and pathological differences, and perhaps two
different forms of hypertensive nephropathy affect black
Table 2. Summary of the published trials on angiotensin converting enzyme inhibition (ACEi)
Study Year
Follow-up
months
ACEi Other antihypertensive drugs
N patients ESRD Death Drop out N patients ESRD Death Drop out
Zucchelli et al [29] 1992 36 60 7 1 15 61 14 0 14
Kemper et al [30] 1992 24 35 10 1 4 35 13 4 17
Hannedouche et al [31] 1994 36 52 10 1 11 48 17 2 19
Ihle et al [32] 1996 24 36 7 1 16 34 9 1 10
Maschio et al [33] 1996 36 300 1 8 42 283 1 1 2
Remuzzi et al [13] 1997 36 78 17 2 16 88 29 1 17
Table 3. Different renal diseases classified as hypertension-related
ESRD or hypertensive nephrosclerosis
c True hypertensive nephrosclerosis (or nephroangiosclerosis)
nephropathy
c Ischemic renal disease (or atheromatous renovascular disease):
Renal artery stenosis
Cholesterol mycroembolization
Severe tubulo-interstitial damage
Table 4. Final diagnosis of 58 consecutive patients clinically considered
as having hypertensive nephrosclerosis
Final diagnosis N patients
Analgesic nephropathy 1
Unsuspected IgA nephropathy 1
Immunotactoid nephropathy 1
Light-chain deposition disease without free light chains
in the plasma and urine
1
Unclassified 8
Atheromatous renovascular disease 19
True hypertensive nephrosclerosis 27
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and white patients [40]. In favor of a high and true
incidence of hypertensive nephrosclerosis in African Amer-
icans are the results of renal biopsies performed during the
pilot phase of the African American Study of Kidney
Diseases (AAKS). Among 39 adequate tissue specimens,
35 show vascular lesions consistent with the clinical diag-
nosis of hypertensive nephrosclerosis, and in 2 cases cho-
lesterol emboli were found [46].
Non-malignant essential hypertension is associated with
vascular changes collectively known as hypertensive ne-
phrosclerosis (or nephroangiosclerosis). Two main features
of vascular lesions are present: (1) arteriolar hyalinosis
(predominantly preglomerular) with subendothelial depos-
its of homogeneous eosinophilic material, and (2) intimal
thickening with medial hyperthrophy subsequently trans-
formed into medial fibrosis (so-called fibroplastic intimal
thickening). Vascular alterations are accompanied by vari-
ous degrees of ischemic glomerular changes, some degrees
of focal and segmental glomerulosclerosis and tubulointer-
stitial fibrosis. These lesions may be responsible for the
appearance of renal failure over a long period of time,
without the possibility of separating the pathologic changes
attributed to the effect of hypertension from those of
advanced age (nonspecific renal lesions) [40, 47]. Why only
a few individuals with essential hypertension, at least
Caucasians, develop progressive renal disease is not known.
Essential hypertension is likely to be a very heterogeneous
syndrome in which high blood pressure may be variously
associated with dyslipidemia, insulin resistance, hyperuri-
cemia, alterations in immune response, and so on [48].
Hence, it may be that some subpopulations of hypertensive
patients (for instance, those showing microalbuminuria, or
salt-sensitivity) are particularly prone to developing renal
insufficiency.
ATHEROMATOUS RENOVASCULAR DISEASE
Over the last decade, renal atheromatous disease has
been the subject of intensive work [42, 44, 47]. It may cause
progressive renal insufficiency either by causing renal ar-
tery stenosis (RAS) or by being the source of renal
cholesterol embolization. There is no reliable epidemiolog-
ical information on the frequency of RAS, but some
observations suggest that it may be very frequent in the
elderly and is often undiagnosed. Some autopsy studies
reported a very frequent RAS number in Caucasian pa-
tients with generalized atherosclerosis. Moreover, in many
angiographic studies [43], unsuspected RAS was found with
a frequency of 20 to 30% in Caucasians over 50 years of age
who had severe atherosclerosis with angiography per-
formed due to peripheral vascular disease or coronary
artery stenosis. Since atheromatous RAS may be a progres-
sive disease [43, 44, 49, 50], so-called ischemic renal
disease, it may cause ESRD as has been documented in
recent studies with a frequency of 14% to 22% among
ESRD, usually in Caucasians and the aged. Besides RAS,
cholesterol microembolization may be an important mech-
anism of renal damage mimicking the lesions of hyperten-
sive nephrosclerosis [44, 48]. Cholesterol embolization is
very frequently found at autopsy with a frequency varying
from 4.7 to 17.7% of white patients over 50 years of age
with severe aortic atheroma or aortic aneurism. Apart from
the acute scenario, in many cases the disease is chronic and
relatively asymptomatic [43, 44, 50]. The presence of the
characteristic needle-shaped crystals in the glomeruli or
renal arteries may be frequently observed in Caucasian
patients with a clinical diagnosis of hypertensive nephro-
sclerosis submitted to renal biopsy, while it seems more
rare, but not absent, in African Americans (2 out of the 39
patients of the AAKS [46].
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